(Q77146377)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

title

Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

S E Sinclair

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

L Frighetto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

P S Loewen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

R Sunderji

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

P Teal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

S C Fagan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

C A Marra

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

publication date

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

927-936

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11700779%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00019053-200119090-00004

3 December 2019

exact match

0 references

cites work

Patient preferences for stroke outcomes

1 reference

12 December 2020

Interobserver agreement for the assessment of handicap in stroke patients.

1 reference

12 December 2020

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators

1 reference

12 December 2020

Tissue plasminogen activator for acute ischemic stroke

1 reference

12 December 2020

Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke

1 reference

12 December 2020

Thrombolysis for acute ischaemic stroke

1 reference

12 December 2020

Treating acute stroke patients with intravenous tPA. The OSF stroke network experience

1 reference

12 December 2020

Cost considerations in the pharmacological prevention and treatment of stroke

1 reference

12 December 2020

Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke

1 reference

12 December 2020

Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group

1 reference

12 December 2020

Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study

1 reference

12 December 2020

Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience

1 reference

12 December 2020

The stroke pharmacopeia: current medical therapies.

1 reference

12 December 2020

Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.

1 reference

12 December 2020

Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Hea

1 reference

12 December 2020

Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice

1 reference

12 December 2020

Cost of acute stroke care in Toronto, Canada

1 reference

12 December 2020

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

1 reference

12 December 2020

Early intravenous thrombolysis for acute ischemic stroke in a community-based approach

1 reference

12 December 2020

Decreasing costs of stroke hospitalization in Toronto

1 reference

12 December 2020

An introduction to Markov modelling for economic evaluation

1 reference

12 December 2020